Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 6/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | PTGES | O14684 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734022 | 0.88 | GRM2 (0.76) | GRM2NR3C1PGRPTGES | |
| SCHEMBL6732221 | 0.86 | GRM2 (0.80) | GRM2NR3C1SMN1; SMN2PGRMMP2 | |
| SCHEMBL6730842 | 0.85 | GRM2 (0.67) | GRM2NR3C1PGRPTGESALOX5 | |
| SCHEMBL7095387 | 0.84 | ALDH1A1 (0.60) | GRM2SMN1; SMN2 | |
| SCHEMBL6732961 | 0.83 | NR3C1 (0.56) | GRM2NR3C1PGRPTGESALOX5 | |
| SCHEMBL6727879 | 0.83 | GRM2 (0.65) | GRM2NR3C1PGRPTGESALOX5 | |
| SCHEMBL6731087 | 0.81 | GRM2 (0.60) | GRM2NR3C1PGR | |
| SCHEMBL6736419 | 0.80 | GRM2 (0.71) | GRM2NR3C1SMN1; SMN2PGRMMP2 | |
| SCHEMBL6732942 | 0.80 | SMN1; SMN2 (0.58) | GRM2NR3C1SMN1; SMN2PGRMMP2 | |
| SCHEMBL10560384 | 0.79 | PKM (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | GRM2 3/4885NR3C1 336/4885SMN1; SMN2 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.